| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 80 | 2024 | 1664 | 13.060 |
Why?
|
| Immunotherapy, Adoptive | 39 | 2024 | 1763 | 4.570 |
Why?
|
| Antigens, CD19 | 24 | 2024 | 577 | 3.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 15 | 2023 | 1039 | 2.930 |
Why?
|
| Lymphoma, B-Cell | 13 | 2023 | 895 | 2.740 |
Why?
|
| Biological Products | 12 | 2024 | 274 | 2.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 61 | 2023 | 15862 | 2.270 |
Why?
|
| Rituximab | 36 | 2023 | 1528 | 2.060 |
Why?
|
| Lymphoma, Follicular | 13 | 2023 | 587 | 1.900 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2022 | 1146 | 1.840 |
Why?
|
| Lymphoma | 8 | 2023 | 1467 | 1.270 |
Why?
|
| Lymphoma, Mantle-Cell | 11 | 2022 | 713 | 1.210 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 8 | 2023 | 301 | 1.150 |
Why?
|
| Cyclophosphamide | 22 | 2023 | 3001 | 1.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2023 | 6550 | 1.020 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2023 | 1249 | 1.010 |
Why?
|
| Hodgkin Disease | 9 | 2020 | 1429 | 1.000 |
Why?
|
| Piperidines | 8 | 2023 | 1035 | 0.990 |
Why?
|
| Humans | 160 | 2024 | 261506 | 0.960 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2023 | 833 | 0.960 |
Why?
|
| Vincristine | 19 | 2023 | 1511 | 0.950 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 4 | 2019 | 181 | 0.870 |
Why?
|
| Prednisone | 15 | 2023 | 984 | 0.870 |
Why?
|
| Doxorubicin | 23 | 2023 | 3005 | 0.870 |
Why?
|
| Proteolysis | 1 | 2024 | 370 | 0.820 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 224 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 13 | 2020 | 864 | 0.760 |
Why?
|
| T-Lymphocytes | 12 | 2023 | 3869 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 810 | 0.750 |
Why?
|
| Oligonucleotides | 1 | 2021 | 227 | 0.740 |
Why?
|
| Mediastinal Neoplasms | 4 | 2018 | 423 | 0.720 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 5178 | 0.710 |
Why?
|
| Treatment Outcome | 40 | 2022 | 32848 | 0.700 |
Why?
|
| Aged | 66 | 2024 | 70117 | 0.690 |
Why?
|
| Salvage Therapy | 10 | 2021 | 2054 | 0.680 |
Why?
|
| Immunoconjugates | 1 | 2022 | 279 | 0.660 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 246 | 0.650 |
Why?
|
| Histiocytosis, Sinus | 1 | 2019 | 86 | 0.650 |
Why?
|
| Circulating Tumor DNA | 5 | 2021 | 235 | 0.620 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2023 | 10035 | 0.610 |
Why?
|
| Adult | 69 | 2022 | 77950 | 0.610 |
Why?
|
| Middle Aged | 70 | 2022 | 86204 | 0.600 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2022 | 113 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 4757 | 0.590 |
Why?
|
| Pyrazoles | 5 | 2019 | 1471 | 0.570 |
Why?
|
| Bile Ducts | 1 | 2016 | 113 | 0.530 |
Why?
|
| Resorcinols | 1 | 2015 | 27 | 0.520 |
Why?
|
| Recurrence | 12 | 2021 | 4758 | 0.510 |
Why?
|
| Isoxazoles | 1 | 2015 | 81 | 0.500 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2019 | 1048 | 0.490 |
Why?
|
| Adenine | 7 | 2023 | 631 | 0.480 |
Why?
|
| Male | 70 | 2022 | 123000 | 0.470 |
Why?
|
| Transplantation, Autologous | 7 | 2022 | 1914 | 0.470 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2021 | 502 | 0.470 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 196 | 0.470 |
Why?
|
| Cholestasis | 1 | 2016 | 203 | 0.470 |
Why?
|
| Aged, 80 and over | 33 | 2021 | 29902 | 0.470 |
Why?
|
| Female | 74 | 2022 | 141928 | 0.460 |
Why?
|
| Standard of Care | 3 | 2023 | 243 | 0.450 |
Why?
|
| Young Adult | 29 | 2021 | 21445 | 0.450 |
Why?
|
| DNA | 1 | 2021 | 2693 | 0.440 |
Why?
|
| Retrospective Studies | 35 | 2024 | 37905 | 0.430 |
Why?
|
| Bone Resorption | 1 | 2012 | 138 | 0.420 |
Why?
|
| Pyrimidines | 7 | 2019 | 3518 | 0.420 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2023 | 103 | 0.410 |
Why?
|
| Antineoplastic Agents | 9 | 2023 | 14289 | 0.410 |
Why?
|
| Disease-Free Survival | 21 | 2021 | 10001 | 0.410 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 2390 | 0.400 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2022 | 1226 | 0.390 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 198 | 0.380 |
Why?
|
| Diphosphonates | 1 | 2012 | 262 | 0.380 |
Why?
|
| Survival Analysis | 12 | 2023 | 9180 | 0.380 |
Why?
|
| Positron-Emission Tomography | 8 | 2022 | 2173 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 3 | 2021 | 125 | 0.370 |
Why?
|
| Models, Theoretical | 1 | 2015 | 785 | 0.370 |
Why?
|
| Combined Modality Therapy | 11 | 2021 | 8865 | 0.370 |
Why?
|
| Benzamides | 3 | 2021 | 1832 | 0.360 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.360 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2021 | 923 | 0.360 |
Why?
|
| Neoplasms | 4 | 2022 | 15193 | 0.350 |
Why?
|
| Prognosis | 25 | 2022 | 21713 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 3 | 2016 | 2330 | 0.350 |
Why?
|
| CD5 Antigens | 1 | 2010 | 112 | 0.350 |
Why?
|
| Radiotherapy | 6 | 2020 | 1824 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 5 | 2016 | 4367 | 0.330 |
Why?
|
| Dexamethasone | 6 | 2021 | 1450 | 0.320 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1870 | 0.320 |
Why?
|
| Etoposide | 7 | 2021 | 870 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 2054 | 0.300 |
Why?
|
| Survival Rate | 19 | 2021 | 12221 | 0.300 |
Why?
|
| Imidazoles | 1 | 2012 | 999 | 0.290 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.290 |
Why?
|
| Sulfonamides | 3 | 2021 | 1823 | 0.290 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 10331 | 0.280 |
Why?
|
| Methotrexate | 6 | 2022 | 999 | 0.280 |
Why?
|
| Genes, myc | 3 | 2017 | 358 | 0.270 |
Why?
|
| Critical Illness | 2 | 2022 | 714 | 0.270 |
Why?
|
| Mutation | 10 | 2024 | 15179 | 0.260 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 846 | 0.260 |
Why?
|
| Lymphoma, T-Cell | 2 | 2019 | 361 | 0.250 |
Why?
|
| Receptors, CCR7 | 1 | 2024 | 39 | 0.240 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 538 | 0.240 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2022 | 406 | 0.240 |
Why?
|
| Piperazines | 1 | 2012 | 2101 | 0.230 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 2278 | 0.230 |
Why?
|
| Leukocyte Common Antigens | 1 | 2024 | 188 | 0.230 |
Why?
|
| Disease Management | 5 | 2020 | 1052 | 0.230 |
Why?
|
| Neutropenia | 4 | 2021 | 968 | 0.230 |
Why?
|
| Germinal Center | 3 | 2021 | 161 | 0.230 |
Why?
|
| CD28 Antigens | 1 | 2024 | 202 | 0.220 |
Why?
|
| Hepatitis E virus | 1 | 2022 | 7 | 0.220 |
Why?
|
| Hepatitis E | 1 | 2022 | 9 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1443 | 0.220 |
Why?
|
| Stem Cell Transplantation | 5 | 2022 | 1360 | 0.210 |
Why?
|
| Research Personnel | 1 | 2024 | 156 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2019 | 2104 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 8873 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 1493 | 0.210 |
Why?
|
| Neoplasm Staging | 14 | 2020 | 13658 | 0.200 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 22 | 0.200 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 1294 | 0.200 |
Why?
|
| Precision Medicine | 2 | 2019 | 1154 | 0.200 |
Why?
|
| Follow-Up Studies | 13 | 2021 | 14889 | 0.200 |
Why?
|
| Depsipeptides | 2 | 2019 | 78 | 0.200 |
Why?
|
| Biopsy | 3 | 2019 | 3443 | 0.200 |
Why?
|
| Exanthema | 1 | 2023 | 211 | 0.200 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 2527 | 0.190 |
Why?
|
| Adolescent | 16 | 2021 | 31252 | 0.190 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 23 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2019 | 11965 | 0.190 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2020 | 15 | 0.190 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.180 |
Why?
|
| Primaquine | 1 | 2019 | 2 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2022 | 199 | 0.180 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 36 | 0.170 |
Why?
|
| Intensive Care Units | 2 | 2022 | 717 | 0.170 |
Why?
|
| Drug Administration Schedule | 5 | 2017 | 3472 | 0.170 |
Why?
|
| Burkitt Lymphoma | 1 | 2022 | 335 | 0.170 |
Why?
|
| Diarrhea | 3 | 2022 | 686 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2019 | 266 | 0.160 |
Why?
|
| Gastric Mucosa | 2 | 2019 | 613 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2022 | 6869 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2022 | 1234 | 0.160 |
Why?
|
| Remission Induction | 4 | 2018 | 3569 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2022 | 9244 | 0.160 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 2864 | 0.160 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 783 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3719 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 544 | 0.150 |
Why?
|
| Nervous System Diseases | 2 | 2019 | 500 | 0.150 |
Why?
|
| Organs at Risk | 1 | 2020 | 514 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2019 | 441 | 0.150 |
Why?
|
| Genes, bcl-2 | 2 | 2014 | 166 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.150 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 7551 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 3251 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2019 | 574 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.140 |
Why?
|
| Testicular Neoplasms | 2 | 2018 | 529 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6207 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 543 | 0.140 |
Why?
|
| Syndrome | 2 | 2017 | 1351 | 0.140 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 184 | 0.140 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 171 | 0.140 |
Why?
|
| Melphalan | 1 | 2019 | 834 | 0.140 |
Why?
|
| Radiotherapy Dosage | 6 | 2020 | 3842 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1014 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2019 | 498 | 0.130 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 1022 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Interferons | 1 | 2017 | 291 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2021 | 1678 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 1248 | 0.130 |
Why?
|
| Bortezomib | 1 | 2017 | 543 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 112 | 0.130 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2015 | 38 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2016 | 684 | 0.130 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2015 | 38 | 0.130 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 657 | 0.130 |
Why?
|
| Bilirubin | 1 | 2016 | 221 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 5159 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.130 |
Why?
|
| Splenic Diseases | 1 | 2015 | 56 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 589 | 0.120 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 884 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 247 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2019 | 769 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2017 | 550 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 222 | 0.120 |
Why?
|
| Cytarabine | 5 | 2022 | 1973 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 907 | 0.120 |
Why?
|
| Thalidomide | 2 | 2014 | 569 | 0.120 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 206 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2017 | 428 | 0.120 |
Why?
|
| Topotecan | 1 | 2014 | 239 | 0.120 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2576 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 260 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 441 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2021 | 12873 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2017 | 612 | 0.110 |
Why?
|
| Edema | 1 | 2015 | 267 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 301 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 1299 | 0.110 |
Why?
|
| Helicobacter pylori | 2 | 2020 | 1295 | 0.110 |
Why?
|
| Transcriptome | 2 | 2020 | 1859 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 1301 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 14551 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 223 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 788 | 0.110 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 15694 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2023 | 3341 | 0.100 |
Why?
|
| Neutrophils | 1 | 2016 | 835 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 4988 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2019 | 2218 | 0.100 |
Why?
|
| Isoenzymes | 1 | 2014 | 614 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 7548 | 0.100 |
Why?
|
| Leukapheresis | 2 | 2022 | 152 | 0.100 |
Why?
|
| Leukemia | 1 | 2020 | 1635 | 0.100 |
Why?
|
| Genomics | 2 | 2020 | 2738 | 0.100 |
Why?
|
| Patient Selection | 2 | 2020 | 2055 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 966 | 0.090 |
Why?
|
| Internet | 1 | 2015 | 706 | 0.090 |
Why?
|
| Bone Density | 1 | 2012 | 476 | 0.090 |
Why?
|
| Prednisolone | 1 | 2010 | 123 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 803 | 0.090 |
Why?
|
| Cell Division | 1 | 2014 | 2489 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2992 | 0.090 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2022 | 436 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2195 | 0.080 |
Why?
|
| Fatigue | 1 | 2015 | 1239 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1245 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 1665 | 0.080 |
Why?
|
| Texas | 1 | 2019 | 6311 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2018 | 1391 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 2638 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 4320 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2020 | 726 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.070 |
Why?
|
| Vinblastine | 2 | 2020 | 453 | 0.070 |
Why?
|
| Bleomycin | 2 | 2020 | 467 | 0.070 |
Why?
|
| Gene Expression | 1 | 2015 | 3570 | 0.070 |
Why?
|
| Liver | 1 | 2016 | 2961 | 0.070 |
Why?
|
| Dacarbazine | 2 | 2020 | 485 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4532 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2014 | 4804 | 0.070 |
Why?
|
| Time Factors | 4 | 2021 | 12926 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 2 | 2021 | 1290 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1586 | 0.060 |
Why?
|
| Comorbidity | 2 | 2022 | 2352 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 5673 | 0.060 |
Why?
|
| Lung | 1 | 2015 | 3151 | 0.060 |
Why?
|
| United States | 4 | 2022 | 15433 | 0.060 |
Why?
|
| Vidarabine | 2 | 2019 | 1341 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4078 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2023 | 2358 | 0.050 |
Why?
|
| Polyamines | 1 | 2022 | 75 | 0.050 |
Why?
|
| Disease Progression | 3 | 2019 | 6682 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 72 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 177 | 0.050 |
Why?
|
| Ribavirin | 1 | 2022 | 178 | 0.050 |
Why?
|
| Biomarkers | 3 | 2017 | 5047 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 227 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 225 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2291 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 4821 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 151 | 0.050 |
Why?
|
| North America | 1 | 2021 | 314 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4849 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 194 | 0.050 |
Why?
|
| Morpholines | 1 | 2021 | 289 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2020 | 73 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3821 | 0.050 |
Why?
|
| Thioguanine | 1 | 2019 | 68 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 649 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 348 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2023 | 1144 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2022 | 582 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 130 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 299 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 184 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4298 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 2020 | 224 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2019 | 301 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 124 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 495 | 0.040 |
Why?
|
| Advance Care Planning | 1 | 2019 | 86 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2018 | 101 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 1681 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 698 | 0.040 |
Why?
|
| Beijing | 1 | 2017 | 13 | 0.040 |
Why?
|
| Autografts | 1 | 2018 | 165 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 5687 | 0.040 |
Why?
|
| Chicago | 1 | 2017 | 40 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2020 | 434 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2019 | 288 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 2594 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 1013 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 30 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 142 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2017 | 216 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 140 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 650 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2017 | 344 | 0.040 |
Why?
|
| Antigens | 1 | 2017 | 292 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 276 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 666 | 0.030 |
Why?
|
| Epistaxis | 1 | 2015 | 30 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 202 | 0.030 |
Why?
|
| Hematology | 1 | 2017 | 104 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 323 | 0.030 |
Why?
|
| Gastritis | 1 | 2019 | 373 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2017 | 587 | 0.030 |
Why?
|
| Orbit | 1 | 2017 | 205 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 130 | 0.030 |
Why?
|
| China | 1 | 2017 | 606 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 242 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 2016 | 91 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1656 | 0.030 |
Why?
|
| Interleukins | 1 | 2017 | 325 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2014 | 47 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 259 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2018 | 7226 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2014 | 38 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1000 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 1053 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 452 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2146 | 0.030 |
Why?
|
| Pyrazines | 1 | 2017 | 495 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 799 | 0.030 |
Why?
|
| Carboplatin | 1 | 2017 | 823 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1742 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 323 | 0.030 |
Why?
|
| Biological Factors | 1 | 2013 | 45 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2017 | 403 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 1900 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 904 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2019 | 3536 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1411 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 4654 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 3045 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 676 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 242 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4314 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 598 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2232 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 4307 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 1546 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 5114 | 0.020 |
Why?
|
| Breast | 1 | 2018 | 1344 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 1216 | 0.020 |
Why?
|
| Proteomics | 1 | 2018 | 1380 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2307 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.020 |
Why?
|
| DNA Damage | 1 | 2018 | 1954 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 1756 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2016 | 1863 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4892 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 7702 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2019 | 2967 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3343 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2017 | 1423 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 59536 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 691 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 34495 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 6295 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1350 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 781 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 4975 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 4938 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2020 | 5270 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 3976 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7222 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 2370 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3022 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 7591 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7573 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 2979 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 17523 | 0.010 |
Why?
|
| Child | 1 | 2017 | 29154 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 6915 | 0.010 |
Why?
|